Its crucial to note that these are general guidelines, and your optimal dosage may vary based on factors such as your age, health status, and treatment goals
We offer medical weight loss, hormone replacement therapy, life extension with rapamycin, and more
Complete protocols by life stage 30s woman protocol (prevention + optimization) Goal : Maintain youthful vitality, prevent early aging Core protocol: Ipamorelin: 100mcg 2x daily CJC-1295: 1mg 2x weekly Optional additions: NAD+ peptides if energy is concern BPC-157 if active/injury-prone GHK-Cu topical for skin prevention Duration : 12-16 weeks, assess results, continue or cycle Cost : $250-400 monthly (core), $400-600 with additions 40s woman protocol (hormone support + anti-aging) Goal : Combat hormonal decline, maintain metabolism and vitality Core protocol: Ipamorelin: 150-200mcg 2x daily CJC-1295: 2mg 2x weekly GHK-Cu: Topical serum to face 2x daily Optional additions: NAD+ peptides for energy Semaglutide if weight gain occurring Duration : Long-term (years), this is maintenance for 40s Cost : $400-600 monthly Menopause protocol (symptom management + health) Goal : Manage menopause symptoms, prevent rapid decline Core protocol: Ipamorelin: 200mcg 2x daily CJC-1295: 2mg 2x weekly PT-141: 1-2mg as needed for libido (1-3x weekly) For weight gain: Add semaglutide (titrate to 1-2mg weekly) For severe symptoms: Add NAD+ peptides for energy Add GHK-Cu for skin/inflammation Duration : Throughout menopause transition (2-5 years), then transition to post-menopause protocol Cost : $500-800 monthly Post-menopause protocol (longevity + vitality) Goal : Healthy aging, prevent age-related decline Core protocol: Ipamorelin: 100-200mcg 2x daily CJC-1295: 2mg 2x weekly NAD+ peptides: 10mg 2x weekly BPC-157: 250mcg daily (maintenance) Duration : Lifelong for optimal healthspan Cost : $500-700 monthly ROI : Preventing one major health issue (fracture, cognitive decline, metabolic disease) pays for decades of peptides
In order to adjust for confounders, the following covariate variables were selected as the independent variable: age, race, ethnicity, sex, BMI, history of chronic kidney disease (CKD), history of congestive heart failure (CHF), history of diabetes, history of gastric surgery, history of gastroparesis, whether bowel prep was used (e.g., underwent same day EGD-flexible sigmoidoscopy or EGD-colonoscopy), history of GLP-1RA use, and other medications known to contribute to delayed gastric emptying
C.HillB
& Jin, T
